18F

Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Radiation, Personality, Brain, Headache, MRI, 18F, Aminolevulinic acid, Cell, Survival, Disease, Seizure, Magnetic resonance imaging, Patient, Committee, Knowledge, Glioma, PET, Tissue, Regulation, Cancer, FDOPA, EMA, IRIS, Nausea, European, Fluorodeoxyglucose (18F), COMP, Somatic symptom disorder, Sponsor, European Commission, Safety, Vomiting, Marketing, Hepatocellular carcinoma, Molecular imaging, Medicine, Pharmaceutical industry

Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Key Points: 


Orphan designation: Florilglutamic acid (18F) Diagnosis of glioma, 21/03/2016 Withdrawn

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Diagnosis, Incidence, Partnership, 18F, Radiation, PET, Recurrence, Radiopharmaceutical, PSMA, Cancer, Janet Woodcock, Chinese, Prostate cancer, Blue Earth, CSCO, Patient, Medical imaging

It marks an important stage in the Blue Earth Diagnostics’ strategy to make flotufolastat (18F) available to patients and clinicians globally.

Key Points: 
  • It marks an important stage in the Blue Earth Diagnostics’ strategy to make flotufolastat (18F) available to patients and clinicians globally.
  • Yanmin Tang, CEO of Sinotau Pharmaceutical Group, said, “Sinotau Pharmaceutical Group is dedicated to the field of new generation radiopharmaceuticals.
  • We are pleased to form this strategic cooperation with Blue Earth Diagnostics and we look forward to making flotufolastat (18F) available to the clinical community in China.
  • It is engineered to advance clinical decision-making by providing useful information to guide treatment planning in men with prostate cancer.

NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress

Retrieved on: 
Tuesday, September 5, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, NETS, 18F, Half-life, EANM, PSMA, Survival, Cancer, Pharmacokinetics, University Hospital of Basel, FAP, Heterotrimeric G protein, Nuclear medicine, Radiopharmaceutical, Doctor of Philosophy, University Hospital of Zürich, Glomus tumor, European Association of Nuclear Medicine, Patient, PET/CT, Entrepreneurship, European Association for the Study of the Liver, Prostate cancer, Medical imaging

NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.

Key Points: 
  • NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.
  • The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation.
  • The programs are part of NUCLIDIUM’s comprehensive pipeline of copper-based radiotheranostics based on its flexible CuTraceTM platform.
  • The positive pre-clinical data for the diagnostic candidates from three of our programs and the preparation for clinical translation represent an important step for NUCLIDIUM.

Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)

Retrieved on: 
Friday, July 21, 2023
Curium, CONDOR, 18F, Prostate cancer, PSMA, Molecular imaging, European Directive on Traditional Herbal Medicinal Products, Cancer, PET, PYTHON, Google Images, Committee, Manuscript, Food and Drug Administration Amendments Act of 2007, MD, Patient, Master of Science, Chief Medical Officer (Ireland), PET/CT, European Medicines Agency, Phase, FDA, Recurrence, MD–PhD, European Journal, Food, European Journal of Nuclear Medicine and Molecular Imaging, Medical imaging, Nuclear medicine

PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical trial which compared [18F] piflufolastat ([18F]DCFPyL) versus [18F]fluoromethylcholine PET/CT in patients with first biochemical recurrence of prostate cancer.

Key Points: 
  • PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical trial which compared [18F] piflufolastat ([18F]DCFPyL) versus [18F]fluoromethylcholine PET/CT in patients with first biochemical recurrence of prostate cancer.
  • The results of the PYTHON trial were published online ahead of print in the European Journal of Nuclear Medicine and Molecular Imaging in June 2023.
  • The PYTHON Study (NCT04734184) was a Phase III, European, multicenter, prospective cross-over trial, to evaluate and compare the detection rates, impact on patient management and safety profiles of [18F]DCFPyL and [18F]fluoromethylcholine, in patients with first biochemical recurrence after initial definitive therapy with curative intent.
  • This study successfully met the primary endpoint.

Introducing Comet: Simplifying Delivery of Digital Services for the Federal Government

Retrieved on: 
Tuesday, July 18, 2023
GSA, Workflow, 18F, Farmer, Research, Government, Comet, TypeScript, JavaScript, CSG, Collection, Government agency, Government Digital Service, Online shopping, React

MetroStar's Client Solution Group (CSG)—a team dedicated to research and development—drew inspiration for the solution from the pioneering efforts of GSA, 18F, and the U.S. Digital Service's establishment of the U.S.

Key Points: 
  • MetroStar's Client Solution Group (CSG)—a team dedicated to research and development—drew inspiration for the solution from the pioneering efforts of GSA, 18F, and the U.S. Digital Service's establishment of the U.S.
  • Historically, USWDS provided MetroStar with an invaluable foundation as they embarked on building the farmers.gov platform in 2018, which now provides farmers with targeted and informative resources from multiple federal agencies.
  • Government agencies are mandated to use USWDS, but many also rely on React, a design library written in JavaScript.
  • "Comet was born from a passion for creating digital services that enhance user experiences," said Johnny Bouder, MetroStar's Principal Software Engineer.

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Retrieved on: 
Tuesday, May 30, 2023
Science, Radiology, Biotechnology, Research, Oncology, Health, FDA, Clinical Trials, Blood pressure, CT, Disease, Emory University School of Medicine, Prostate cancer, Diarrhea, 18F, Associate professor, Winship Cancer Institute, ZERO, PSMA, Food, Food and Drug Administration, Hope, PET, Multimedia, RH, CHES, Radiopharmaceutical, Cell, Prostate, Google Images, MS, MD Anderson Cancer Center, MRI, MD, Patient, Physician, Risk, Division, University, PET/CT, Diagnosis, Recurrence, PSA, Metastasis, Safety, Medical imaging

It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.

Key Points: 
  • It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology.
  • “This event marks a major milestone in the expansion of Blue Earth Diagnostics’ robust prostate cancer portfolio.
  • POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.
  • This new approval will, ultimately, give more options – and hope – to people impacted by prostate cancer.”

Tantech Holdings Ltd to Hold Annual Meeting of Shareholders on December 8, 2022

Retrieved on: 
Wednesday, October 19, 2022
People, News, ISO, U.S. Securities and Exchange Commission, Shenzhen, LTD, Republic, NASDAQ, Corporation, Security (finance), Attention, Technology, Private Securities Litigation Reform Act, Goal, Company, Eastern Time Zone, Room, 18F, Forward-looking statement

Shareholders as of the record date, close of business on November 7, 2022, will be entitled to vote at the meeting.

Key Points: 
  • Shareholders as of the record date, close of business on November 7, 2022, will be entitled to vote at the meeting.
  • The Company has determined that October 31, 2022 should be the deadline for receipt of proposals.
  • Such proposals by mail should be delivered to: Tantech Holdings Ltd, No.
  • In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on: 
Tuesday, September 13, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Clinical Trials, Photon, Single-photon emission computed tomography, Half-life, American Society of Nuclear Cardiology, St. Luke's Hospital, Development, Molecular imaging, Thomas Edison, Twitter, NYSE, MPI, Phase, Research, Hospital, LinkedIn, Society, News, Coronary artery disease, Patient, Intelligence, PET, LNTH, 18F, Luke the Evangelist, Myocardial perfusion imaging, Research and development, Cardiology, Doctor of Philosophy, CAD, Ecosystem, NASDAQ, Death, Neurology, SPECT, GE Healthcare, Congress, Multimedia, ASNC, FACC, Positron emission tomography, Medical imaging, Pharmaceutical industry, MD, Facebook

GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).

Key Points: 
  • GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD).
  • Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
  • This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Retrieved on: 
Tuesday, September 13, 2022
Photon, Single-photon emission computed tomography, Half-life, NORTH, American Society of Nuclear Cardiology, St. Luke's Hospital, Development, Molecular imaging, Thomas Edison, Twitter, NYSE, MPI, Phase, Research, Hospital, LinkedIn, Society, News, Coronary artery disease, Program, Patient, Intelligence, PET, LNTH, 18F, Myocardial perfusion imaging, Luke the Evangelist, Research and development, Cardiology, Doctor of Philosophy, CAD, Ecosystem, NASDAQ, Death, Neurology, SPECT, GLOBE, GE Healthcare, Congress, ASNC, FACC, Positron emission tomography, Medical imaging, Pharmaceutical industry, MD, Facebook

Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.

Key Points: 
  • Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease.
  • This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.
  • GE Healthcare has led the funding and development of [18F]flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).

Aquia Inc. Joins the Digital Services Coalition of Companies Driving Government Transformation

Retrieved on: 
Friday, August 19, 2022
Adoption, Technology, Government, DNA, DE, Partnership, Aquia, 18F, Public sector, DSC, Digital, Government Digital Service, Presidential Innovation Fellows, Organization, Public relations

BALTIMORE, Aug. 19, 2022 /PRNewswire/ -- Aquia Inc., a Service-Disabled Veteran-Owned Small Business specializing in cloud and cybersecurity professional services, today announced that it has joined the Digital Services Coalition (DSC) of companies working to make the government work better through digital change.

Key Points: 
  • BALTIMORE, Aug. 19, 2022 /PRNewswire/ -- Aquia Inc., a Service-Disabled Veteran-Owned Small Business specializing in cloud and cybersecurity professional services, today announced that it has joined the Digital Services Coalition (DSC) of companies working to make the government work better through digital change.
  • There are organizations inside the government (United States Digital Service/Corp, 18F, Presidential Innovation Fellows) that are already spearheading efforts to improve how government delivers services to the American public.
  • "Aquia and the DSC have a lot of the same characteristics as organizations," said Aquia Chief Executive Officer, David Maskeroni.
  • At Aquia, we value trust, accountability, transparency, and diversity; and we've built these tenants into the DNA of our company.